In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the US biosimilar ranibizumab, CIMERLI, from Coherus BioSciences, Inc. The deal, valued at an upfront cash purchase of USD 170 million, encompasses a biologics license application, product inventory, specialized ophthalmology sales […]
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market, has entered into a pivotal Distribution Agreement with Sandoz. This agreement confers exclusive rights to Sandoz for the promotion, sale, and distribution of the Adalimumab biosimilar for subcutaneous injection [FKB] in Japan. This move represents a significant […]
Sandoz, a division of the Swiss pharmaceutical giant Novartis, has finalized a deal to acquire the cephalosporin antibiotics business from GSK (GlaxoSmithKline) for up to $500 million. This acquisition grants Sandoz global rights to three major antibiotic brands: Zinnat, Zinacef, and Fortum in over 100 markets, significantly enhancing its position in the antibiotics market. Exclusions […]
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira (adalimumab). This agreement marks a major milestone in Pfizer’s mission to broaden its portfolio of biosimilar medications, as it acquires a non-exclusive patent license to market […]
Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of a sterile manufacturing facility for injectable medicines located in Boucherville, Quebec. This strategic acquisition, initially announced in late May 2018, marks Avara’s first foray into the Canadian market and significantly enhances its capabilities in sterile processing. The […]
In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. This approval encompasses all indications of the reference drug, including treatment for rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis, and ulcerative colitis, marking a pivotal step in broadening access to […]
Slayback Pharma LLC has announced the launch of its new generic treatment for genital herpes, Generic Zovirax Ointment (Acyclovir Ointment) 5%, in the United States, marketed through an out-licensing agreement with Sandoz Inc., a generic pharmaceuticals subsidiary of Novartis AG. Strategic Partnership and Market Entry The launch follows the successful acquisition of an Abbreviated New […]
